Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 9:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 20,701 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Myelogenous Leukemia
Interventions
imatinib mesilate, interferon-alpha (INF-a), cytarabine (ARA-C)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
62
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 50 more
Conditions
Mantle Cell Lymphoma
Interventions
Bortezomib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Methotrexate, Rituximab, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 79 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Primary Renal Allograft Candidate, Kidney Transplantation
Interventions
Anti-thymocyte Globulin (Rabbit), belatacept, methylprednisolone, basiliximab, mycophenolate mofetil, tacrolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia
Conditions
Presumed Ocular Histoplasmosis (POHS)
Interventions
ranibizumab, verteporfin
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Indianapolis, Indiana • St Louis, Missouri
Conditions
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
Interventions
olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
33
States / cities
Mobile, Alabama • Tucson, Arizona • Duarte, California + 28 more
Conditions
Pancreatic Cancer
Interventions
Questionnaires, Blood Draws, Pedometer
Behavioral · Procedure · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Atrial Fibrillation (AF)
Interventions
Not listed
Lead sponsor
McMaster University
Other
Eligibility
18 Years to 100 Years
Enrollment
1,780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Evanston, Illinois • Detroit, Michigan • Great Neck, New York + 1 more
Conditions
Malignant Neoplasms Brain
Interventions
RNA-loaded dendritic cell vaccine, basiliximab
Biological · Drug
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
HIV/AIDS
Interventions
Maraviroc
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Friedreich Ataxia
Interventions
Spinal tap for CSF collection, Venipuncture for blood sample
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Cyclophosphamide, Cytarabine, Filgrastim, Methotrexate, Pegfilgrastim, Ponatinib, Rituximab, Vincristine
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
GSK189075
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Diffuse Large B-Cell Lymphoma, Lymphoma, Diffuse Large-Cell, Diffuse Large-Cell Lymphoma, Lymphoma
Interventions
Bendamustine, Rituximab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Boone, North Carolina • Chapel Hill, North Carolina • Concord, North Carolina + 4 more
Conditions
Hepatocellular Carcinoma, HCC
Interventions
Nivolumab, Ipilimumab, Cabozantinib, Transarterial Chemoembolization
Drug · Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orange, California
Conditions
Colorectal Cancer, Non-Small Cell Lung Cancer
Interventions
GDC-1971, Osimertinib, Cetuximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Nashville, Tennessee • San Antonio, Texas
Active, not recruiting Phase 1 Interventional

CD4^LVFOXP3 in Participants With IPEX

NCT05241444
Conditions
IPEX
Interventions
CD4^LVFOXP3
Biological
Lead sponsor
Bacchetta, Rosa, MD
Other
Eligibility
4 Months to 35 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Breast Cancer
Interventions
trastuzumab, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
New York, New York
Conditions
Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration, Resection, Temozolomide, Triapine
Procedure · Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 4 Interventional Results available

Intraoperative Glucose Control in Liver Transplant

NCT00780026
Conditions
Liver Transplant
Interventions
insulin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
HIV Infections
Interventions
Adaptavir (monomeric DAPTA)
Drug
Lead sponsor
Rapid Laboratories Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Healthy
Interventions
dolutegravir
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Recruiting Not applicable Interventional Accepts healthy volunteers

Blood Flow Restriction Training in Patients With Lower Extremity Fractures

NCT06496035
Conditions
Tibial Fractures, Lower Extremity Fracture
Interventions
Blood Flow Restriction with low load exercise, Therapeutic Exercise
Device · Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Lung Cancer
Interventions
Artificial Intelligence (AI) test, Research-use-only multimodal AI risk model
Diagnostic Test
Lead sponsor
University of Illinois Chicago
Other
Eligibility
50 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Blood Cancer, Leukemia
Interventions
Cyclosporine, Anti-thymocyte globulin (ATG), Mycophenolate mofetil (MMF), Filgrastim, Total Lymphoid Irradiation (TLI)
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 70 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Stanford, California